|
|
|
MIRA INFORM REPORT
|
Report No. : |
499534 |
|
Report Date : |
27.03.2018 |
IDENTIFICATION DETAILS
|
Name : |
QILU TIANHE PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No. 849 Dongjia Town, Licheng District, Ji’nan, Shandong Province
250105 PR |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
30.06.2017 |
|
|
|
|
Date of Incorporation : |
07.12.2006 |
|
|
|
|
Com. Reg. No.: |
9137010079261718XR |
|
|
|
|
Legal Form : |
Chinese-foreign equity joint
venture enterprise |
|
|
|
|
Line of Business : |
Manufacturing and selling active pharmaceutical
ingredients (amikacin, buflomedil hydrochloride, amikacin sulfate, tazobactam,
hydroxyurea, carmofur, tegafur, uracil), and psychotropic drugs (alprazolam
active pharmaceutical ingredients). |
|
|
|
|
No. of Employees : |
1,409 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A+ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state-support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual liberalization. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi (RMB) after the currency was accepted as part of the IMF’s special drawing rights basket. After engaging in one-way, large-scale intervention to resist appreciation of the RMB for a decade, China’s 2016 intervention in foreign exchange markets has sought to prevent a rapid RMB depreciation that would have negative consequences for the United States, China, and the global economy.
China’s economic growth has slowed since 2011. The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) servicing its high corporate debt burdens to maintain financial stability; (c) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (d) dampening speculative investment in the real estate sector; (e) reducing industrial overcapacity; and (f) raising productivity growth rates through the more efficient allocation of capital. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. Under President XI Jinping, Beijing has signaled its understanding that China's long-term economic health depends on giving the market a more decisive role in allocating resources, but has moved slowly on market-oriented reforms because of potential negative consequences for stability and short-term economic growth. He has also increased state-control over key sectors and Party control over state-owned enterprises. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time.
|
Source
: CIA |
COMPANY
NAME AND ADDRES
|
COMPANY NAME |
Qilu Tianhe Pharmaceutical Co., Ltd. |
|
CURRENT ADDRESS/ REGISTERED
ADDRESS |
No. 849 Dongjia Town, Licheng
District, Ji’nan, Shandong Province 250105 PR China |
|
TEL. NO. |
86 (0)
531-83128588/83127714/83128396 |
|
FAX NO. |
86 (0) 531-83128097 |
EXECUTIVE
SUMMARY
Date of Registration : DECember 7, 2006
Unified social credit code : 9137010079261718XR
LEGAL FORM :
CHINESE-FOREIGN EQUITY JOINT VENTUREENTERPRISE
REGISTERED CAPITAL : CNY 90,000,000
staff : 1,409
BUSINESS CATEGORY : manufacturing & TRADING
REVENUE : CNY
549,832,000 (FROM JAN. 1, 2017 TO JUN. 30, 2017)
EQUITIES : CNY
1,548,762,000 (AS OF JUN. 30, 2017)
WEBSITE : www.qilu-tianhe.com
E-MAIL : export@qilu-pharma.com
PAYMENT : REGULAR
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : fairly good
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
Adopted
abbreviations (as follows)
SC -
Subject Company (the company inquired by you)
N/A – Not
available
CNY –
China Yuan Ren Min Bi
OPERATIONAL
TREND & GENERAL REPUTATION
This section aims at indicating the relative positions of SC
in respect of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL
STATUS & HISTORY
SC was established as Chinese-foreign equity joint venture enterprise of PRC with State
Administration of Industry & Commerce (SAIC) under unified social credit
code: 9137010079261718XR.
SC’s registered capital: CNY 90,000,000
SC’s paid-in capital: CNY 90,000,000
Registration Change Record:
|
Date |
Change of Contents |
Before the change |
After the change |
|
2017-9-1 |
Registration No./ Unified
Social Credit Code |
370000400003356 |
9137010079261718XR |
Current Co search indicates SC’s shareholders & chief
executives are as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
Antibiotics Hong Kong International
Limited (Hong Kong) |
25 |
|
Shandong Qilu Pharmaceutical
Group Co., Ltd. |
75 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative,
Chairman, General Manager and Director |
Li
Baoyong |
|
Director |
Fan
Changying |
|
Chen
Lianbing |
|
|
Wu
Ke |
|
|
Yang
Chunliang |
|
|
Supervisor |
Zhao
Fengwei |
RECENT
DEVELOPMENT
No recent development was found during our checks at
present.
SHAREHOLDER
CHART & BACKGROUND
Name %
of Shareholding
Antibiotics Hong Kong International
Limited (Hong Kong) 25
Shandong Qilu Pharmaceutical
Group Co., Ltd. 75
Antibiotics
Hong Kong International Limited (Hong Kong)
-----------------------------------------------------------------------------
Date of Registration: February 1, 1994
Registration No.: 0463233
Legal Form: Private
Status: Live
Shandong
Qilu Pharmaceutical Group Co., Ltd.
--------------------------------------------------------------
Unified Social Credit Code:
91370100MA3D431N9X
Date of Registration: January 10,
2017
Registered Capital: CNY
50,000,000
Legal Representative: Li Yan
MANAGEMENT
Li Baoyong Legal Representative, Chairman, General Manager and Director
---------------------------------------------------------------------------------------------------------------
Ø Gender:
M
Ø Age:
48
Ø Qualification:
University
Ø Working
experience (s):
At present, working in SC
as legal representative, chairman, general manager, also working in Qilu Tianhe
Pharmaceutical (Leling) Co., Ltd. as legal representative
Director
------------
Fan Changying
Chen Lianbing
Wu Ke
Yang Chunliang
Supervisor
---------------
Zhao Fengwei
BUSINESS
OPERATION
SC’s
registered business scope includes manufacturing and selling active
pharmaceutical ingredients (amikacin, buflomedil hydrochloride, amikacin
sulfate, tazobactam, hydroxyurea, carmofur, tegafur, uracil), and psychotropic
drugs (alprazolam active pharmaceutical ingredients).
SC is
mainly engaged in manufacturing and selling active pharmaceutical ingredients
for antibiotics, antineoplastic agents, blood vessel of heart and brain,
psychotropic drugs and other related active pharmaceutical ingredients,
preparation and intermediate.
SC’s products mainly include:
amikacin, buflomedil hydrochloride, amikacin sulfate, tazobactam, hydroxyurea,
carmofur, tegafur, uracil, alprazolam, etc.
SC sources its materials 100%
from domestic market. SC sells 40% of its products in domestic market, and 60%
to overseas market, mainly U.S.A., Russia, Germany, Poland, Spain, India, South
Korea, etc.
The buying terms of SC include Check, T/T and Credit of
30-60 days. The payment terms of SC include Check, T/T, L/C and Credit of 30-60
days.
*Major Customers*
==============
Pragati
Raw Pharma Pvt Ltd
Sinbiotik
Internacional Sa De Cv
C J
Shah & Co.
Helm
De Mexico S.A.
Aristo
Laboratories Pvt Ltd.
Staff & Office:
--------------------------
SC is
known to have approx. 1,409
staff at present.
SC
owns an area as its operating office & factory of approx. 280,000 sq. meters
at the heading address.
RELATED
COMPANY
SC is known to
have a subsidiary at present.
n
Qilu Tianhe Pharmaceutical (Leling) Co., Ltd.
------------------------------------------------
Unified Social Credit Code:
91371481MA3CFGTC
Date of Registration: August 18,
2016
Registered Capital: CNY
50,000,000
Legal Representative: Li Baoyong
PAYMENT
Overall payment appraisal:
( ) Excellent ( )
Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments
habits and ability to pay. It is based
on the 3 weighed factors: Trade payment experience (through current enquiry
with SC's suppliers), our delinquent payment records and our debt collection
record concerning SC.
Trade payment experience: SC
did not provide any name of trade/service suppliers and we have no other
sources to conduct the enquiry at present.
Delinquent payment record: None
in our database.
Debt collection record: No
overdue amount owed by SC was placed to us for collection within the last 6
years.
BANKING
Basic Bank:
Agricultural Bank of China Ji’nan Industrial North Road
Sub-branch
AC#: 116601040007201
FINANCIALS
Financial
Summary
|
Unit:
CNY’000 |
As of Jun. 30, 2017 |
|
Total
assets |
1,694,160 |
|
|
------------- |
|
Total
liabilities |
145,398 |
|
Equities |
1,548,762 |
|
|
------------- |
|
Unit:
CNY’000 |
From Jan. 1, 2017 to Jun. 30, 2017 |
|
Revenue |
549,832 |
|
Profits |
76,521 |
Important
Ratios
=============
|
|
As of Jun. 30, 2017 |
|
*Liabilities
to assets |
0.09 |
|
*Net
profit margin (%) |
13.92 |
|
*Return
on total assets (%) |
4.52 |
|
*Revenue/Total
assets |
0.32 |
FINANCIAL
COMMENTS
PROFITABILITY:
FAIRLY GOOD
l The
revenue of SC appears fairly good in its line.
l SC’s
net profit margin is fairly good.
l SC’s
return on total assets is fairly good.
LIQUIDITY:
AVERAGE
l
SC’s revenue is in a fair level,
comparing with the size of its total assets.
LEVERAGE:
FAIRLY GOOD
l
The debt ratio of SC is low.
l
The risk for SC to go bankrupt is low.
Overall
financial condition of the SC: Fairly Good.
CONCLUSIONS
SC is considered large-sized in its line with fairly good
financial conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.91 |
|
|
1 |
INR 91.87 |
|
Euro |
1 |
INR 80.26 |
|
CNY |
1 |
INR 10.35 |
Note:
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.